ABIONYX Pharma Provides an Update on Its Activity and Cash Position for the 1 st Quarter 2025
TOULOUSE, France & LAKELAND, Mich.--(BUSINESS WIRE)--Regulatory News:
ABIONYX Pharma (FR0012616852 - ABNX - PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies based on the world's only natural recombinant apoA-I, today provides an update on its activity and cash position as of March 31, 2025.
Selected financial information (IFRS)
ABIONYX Pharma recorded consolidated quarterly sales of nearly €1 million in Q1 2025, down on Q1 2024. This decline is cyclical and reflects a wait-and-see attitude on the part of customers in the context of uncertain US customs policy. In the business dedicated to the discovery and development of innovative therapies designed to improve patients' lives, the Company generated no sales in the quarter, as ABIONYX Pharma continues to provide its bioproduct free of charge in the context of compassionate access applications.
As at March 31, 2025, the Company had cash and cash equivalents of nearly €4.1 million, before receipt of the estimated €1.08 million Research Tax Credit and after receipt of the first €2.17 million tranche of France 2030 funding.
R&D update and anticipated key milestones:
Concerning the rare disease known as 'LCAT Deficiency' (Lecithin Cholesterol Acyl-Transferase deficiency or Norum disease), the Company continues to receive new requests for Compassionate Access Authorization (CAA) for recombinant apoA-I, CER-001, from several hospitals around the world. Last May, ABIONYX Pharma sent the European Medicines Agency (EMA) the clinical results of treated patients, with a view to continuing discussions and obtaining feedback for a future application for Compassionate Access.
With regard to sepsis, ABIONYX Pharma is pursuing its strategic plan to find a strategic partner for its biomedicine.
About ABIONYX Pharma
ABIONYX Pharma is a next-generation biotech company focused on developing innovative medicines for diseases where there is no effective or existing treatment, even the rarest ones. The company expedites the development of novel therapeutics through an extensive expertise in lipid science and a differentiated apoA-I-based technology platform. ABIONYX Pharma is committed to radically improving treatment outcomes in Sepsis and critical care.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
36 minutes ago
- Yahoo
Avangrid Invests In The Next Generation With Its 2025 Summer Internship Program
After receiving more than 9,900 applications, Avangrid welcomes 71 interns this summer, offering aspiring talent in energy a differentiated career experience with a local and global leader. ORANGE, Conn., June 06, 2025--(BUSINESS WIRE)--Avangrid, Inc., a leading energy company and member of the Iberdrola Group, this week launched its 2025 Summer Internship Program. This year, the company welcomes 71 interns from over 50 universities across the United States and abroad, including participants from Spain and Mexico. Interns will be based at Avangrid offices located in New York, Maine, Connecticut, Massachusetts, and Oregon, and will join 20 different departments including IT, Communications, and Networks. "At Avangrid, attracting and nurturing emerging talent is one of our key priorities," said Avangrid CEO Pedro Azagra. "Our internship program is designed to help students strengthen their skills and gain real-world experience before entering the workforce. Through workshops, speaker sessions, and peer networking events like Cohort Connects, we aim to equip them with the tools they need for a successful, differentiated and fulfilling career." Kicking off on June 2, the Internship Experience will demonstrate Avangrid's dedication to career growth by teaching skills such as analytical thinking, project coordination, and professional resilience. New interns will participate in sessions focused on practical, job-ready skills, while returning interns will deepen their learning through speaker sessions with senior leaders who bring those skills to life. "Offering this unique internship experience to students across the nation is essential," said Ignacio Estella, Senior Vice President for Talent & Performance, Innovation and Equal Opportunity. "Our goal is to 'electrify' talent with solid career opportunities in the transformational energy sector with a local and global leader, and to showcase the differentiated career paths that Avangrid can offer to the next generation of professionals." The Internship Experience follows a 70/20/10 learning model designed to maximize growth: 70% of learning happens through hands-on, business-critical projects; 20% through relationship-building with mentors, peers, and leaders; and 10% through formal training, such as workshops and speaker sessions. Interns conclude the program by presenting a five-minute pitch showcasing their achievements—an opportunity that often leads to full-time roles or entry into Avangrid's Rotational Graduate Program. "Being part of this program has already been an incredible opportunity," said June Monasterios, a rising senior at Gannon University and an intern in the Internal Audit team. "Even in just the first week, I've felt both welcomed and inspired. I'm beginning to understand not only the energy industry, but also how to grow as a professional. It's exciting to be part of a company that truly values sustainability, innovation, and its people." About Avangrid: Avangrid, Inc. is a leading energy company in the United States working to meet the growing demand for energy for homes and businesses across the nation through service, innovation, and continued investments by expanding grid infrastructure and energy generation projects. Avangrid has offices in Connecticut, New York, Massachusetts, Maine and Oregon, including operations in 23 states with approximately $47 billion in assets, and has two primary lines of business: networks and power. Through its networks business, Avangrid owns and operates eight electric and natural gas utilities, serving more than 3.3 million customers in New York and New England and in 2024. Through its power generation business, Avangrid owns and operates more than 75 energy generation facilities across the United States producing 10.5 GW of power for over 3.1 million customers. Avangrid employs approximately 8,000 people and has been recognized by JUST Capital as one of the JUST 100 companies – a ranking of America's best corporate citizens in 2025 for the fifth consecutive year. The company was named among the World's Most Ethical Companies in 2025 for the seventh consecutive year by the Ethisphere Institute. Avangrid is a member of the group of companies controlled by Iberdrola, S.A. For more information, visit View source version on Contacts Media Contact: Maria 512-791-3868 Sign in to access your portfolio
Business Wire
41 minutes ago
- Business Wire
Avangrid Invests In The Next Generation With Its 2025 Summer Internship Program
ORANGE, Conn.--(BUSINESS WIRE)--Avangrid, Inc., a leading energy company and member of the Iberdrola Group, this week launched its 2025 Summer Internship Program. This year, the company welcomes 71 interns from over 50 universities across the United States and abroad, including participants from Spain and Mexico. Interns will be based at Avangrid offices located in New York, Maine, Connecticut, Massachusetts, and Oregon, and will join 20 different departments including IT, Communications, and Networks. 'At Avangrid, attracting and nurturing emerging talent is one of our key priorities,' said Avangrid CEO Pedro Azagra. 'Our internship program is designed to help students strengthen their skills and gain real-world experience before entering the workforce. Through workshops, speaker sessions, and peer networking events like Cohort Connects, we aim to equip them with the tools they need for a successful, differentiated and fulfilling career.' Kicking off on June 2, the Internship Experience will demonstrate Avangrid's dedication to career growth by teaching skills such as analytical thinking, project coordination, and professional resilience. New interns will participate in sessions focused on practical, job-ready skills, while returning interns will deepen their learning through speaker sessions with senior leaders who bring those skills to life. 'Offering this unique internship experience to students across the nation is essential,' said Ignacio Estella, Senior Vice President for Talent & Performance, Innovation and Equal Opportunity. 'Our goal is to 'electrify' talent with solid career opportunities in the transformational energy sector with a local and global leader, and to showcase the differentiated career paths that Avangrid can offer to the next generation of professionals.' The Internship Experience follows a 70/20/10 learning model designed to maximize growth: 70% of learning happens through hands-on, business-critical projects; 20% through relationship-building with mentors, peers, and leaders; and 10% through formal training, such as workshops and speaker sessions. Interns conclude the program by presenting a five-minute pitch showcasing their achievements—an opportunity that often leads to full-time roles or entry into Avangrid's Rotational Graduate Program. 'Being part of this program has already been an incredible opportunity,' said June Monasterios, a rising senior at Gannon University and an intern in the Internal Audit team. 'Even in just the first week, I've felt both welcomed and inspired. I'm beginning to understand not only the energy industry, but also how to grow as a professional. It's exciting to be part of a company that truly values sustainability, innovation, and its people.' About Avangrid: Avangrid, Inc. is a leading energy company in the United States working to meet the growing demand for energy for homes and businesses across the nation through service, innovation, and continued investments by expanding grid infrastructure and energy generation projects. Avangrid has offices in Connecticut, New York, Massachusetts, Maine and Oregon, including operations in 23 states with approximately $47 billion in assets, and has two primary lines of business: networks and power. Through its networks business, Avangrid owns and operates eight electric and natural gas utilities, serving more than 3.3 million customers in New York and New England and in 2024. Through its power generation business, Avangrid owns and operates more than 75 energy generation facilities across the United States producing 10.5 GW of power for over 3.1 million customers. Avangrid employs approximately 8,000 people and has been recognized by JUST Capital as one of the JUST 100 companies – a ranking of America's best corporate citizens in 2025 for the fifth consecutive year. The company was named among the World's Most Ethical Companies in 2025 for the seventh consecutive year by the Ethisphere Institute. Avangrid is a member of the group of companies controlled by Iberdrola, S.A. For more information, visit
Yahoo
an hour ago
- Yahoo
IBSA Derma at IMCAS Asia 2025: spotlight on the future of aesthetic medicine in the 10th Anniversary Year of NAHYCO® Technology
IBSA Derma, the dermoaesthetic division of Swiss company IBSA, will participate in the 18th IMCAS Asia Congress in Bangkok, gathering over 3,000 professionals from across the region to explore the future of aesthetic and regenerative medicine. With the presence in the Congress and a dedicated scientific symposium, the company reaffirms its commitment to advancing bioremodeling approaches and promoting a holistic, science-driven vision of authentic beauty. This year marks a key milestone for IBSA Derma: 10 years of NAHYCO® Technology, a patented innovation in hyaluronic acid science that continues to shape the future of tissue regeneration. BANGKOK, June 06, 2025--(BUSINESS WIRE)--IBSA Derma – the dermoaesthetic division of IBSA – once again confirms its leadership in the international aesthetic medicine landscape by participating in the 18th edition of IMCAS Asia, taking place from June 6 to 8 in Bangkok, Thailand. With over 3,000 attendees expected, the event represents a key opportunity for physicians and experts to share the latest innovations and cutting-edge advancements in aesthetic procedures and treatments, staying at the forefront of this dynamic field. As part of the congress, IBSA Derma will host a scientific symposium titled "The Future of Tissue Regeneration with NAHYCO® Technology. Feeling and Seeing the Results with Profhilo® Line" scheduled for Saturday, June 7, from 3:00 to 4:00 pm ICT in Room 1 - Level 2. Internationally renowned speakers – Dr. Lam Bee Lan and Prof. Ofir Artzi – will lead the session, focusing on the evolving approaches in regenerative aesthetic medicine, with particular attention to the clinical impact of hybrid cooperative complexes (HCCs) of hyaluronic acid and their role in tissue regeneration across different anatomical layers affected by aging. HCCs represent a new frontier in hyaluronic acid-based product formulation, made possible through NAHYCO® Technology, IBSA's patented thermal process that celebrates its 10th anniversary this year. This technological breakthrough is the foundation of the Profhilo® line and continues to be a milestone of IBSA Derma's innovation pathway. The Company's presence at IMCAS Asia is part of a broader strategic plan for expansion across the APAC region, an increasingly dynamic and high-potential market. In this context, IBSA Derma strengthened its regional presence last year with the opening of its regional hub in Singapore and the launch of a dedicated platform for Asian Key Opinion Leaders to share their clinical insights and expertise. "The strong growth we are experiencing in the APAC region stems from our solid collaboration with local distributors, which enable us to better understand the specific dynamics and cultural nuances of each market" – says Loy Derris, Business Development Director Dermoaesthetic Division North Asia. "Over the past 18 months, we have achieved remarkable results in countries such as Indonesia, Vietnam, Japan, and India, and we have recently entered the Thai market with great momentum. Looking ahead we are also looking enthusiastically toward promising new markets like Taiwan" – declares Magallon Riza Marie, Senior Strategic Marketing and Operational Lead Dermoaesthetic APAC Region. "Being at IMCAS Asia for the second year in a row is a valuable opportunity to strengthen our dialogue with physicians in the APAC Region and promote our concept of authentic beauty that embraces a holistic and overall wellness-oriented approach" – states Elisa Brozzelli, Brand Activation Manager Dermoaesthetic Division. IBSA Derma will also be present at Booth 8 - Level 2, where visitors can learn more about the latest solutions and innovations in aesthetic medicine. About IBSA IBSA (Institut Biochimique SA) is a Swiss pharmaceutical multinational with 20 subsidiaries across Europe, China, and the United States. Its products are available in over 90 countries, and its R&D activities focus on 10 therapeutic areas. In 2025, IBSA will celebrate the 40th anniversary of its acquisition by current President and CEO, Arturo Licenziati, who has transformed the company into a multinational corporation employing over 2,300 personnel worldwide. IBSA's growth and development can be attributed to its ability to innovate by refining well-known molecules, as well as to its commitment to looking to the future responsibly and transparently, thanks to the dedication and dynamism of its people. About IBSA Derma IBSA has used its experience and expertise in the pharmaceutical field to branch out and develop medical devices for aesthetic medicine based on hyaluronic acid, thus creating a dedicated division: IBSA Derma. Through scientific expertise, continuous research, technological development and a modern production process, IBSA has become one of the leading pharmaceutical companies to produce hyaluronic acid for aesthetic medicine applications. IBSA Derma distinguishes itself in this vast market because it controls the entire product lifecycle, from the biofermentation production of the raw material to the ready-to-use final product in prefilled syringes. View source version on Contacts For further information: Giulia Drei, PR and Communication SpecialistDermoaesthetic Sign in to access your portfolio
